Aileron Therapeutics Employee Directory
Biotechnology ResearchMassachusetts, United States11-50 Employees
Following the acquisition of Lung Therapeutics in October 2023, Aileron is shifting its disease focus to advancing a pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis diseases, including LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit our website.